PREDICTORS OF TRIMODALITY THERAPY USE AND OVERALL SURVIVAL IN PATIENTS WITH STAGE III NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NATIONAL CANCER DATABASE

被引：0
|
作者：
Fidler, Mary Jo [1 ]
Liptay, Micheal [1 ]
Bonomi, Philip [1 ]
Sher, David [1 ]
机构：
[1] Rush Univ, Med Ctr, Chicago, IL USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
trimodality thearpy; chemoradiation; population characteristics;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O02.06
引用
收藏
页码：S137 / S138
页数：2
相关论文
共 50 条
  • [41] Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients
    Rothschild, S., I
    Nachbur, R.
    Herzog, N.
    Passweg, J. R.
    Pless, M.
    ESMO OPEN, 2021, 6 (01)
  • [42] Stage III Non-small Cell Lung Cancer
    Rusch, Valerie W.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 37 (05) : 727 - 735
  • [43] Predictors of radiation therapy (RT) use among Medicare patients with metastatic non-small cell lung cancer (NSCLC)
    Kim, Miranda
    Schrag, Deborah
    Li, Ling
    Chen, Aileen B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29)
  • [44] Lymphopenia as a predictor of survival in chemoradiation (CRT)-treated stage III non-small cell lung cancer (NSCLC).
    Yellu, Mahender
    Fakhrejahani, Farhad
    Ying, Jun
    Mierzwa, Michelle
    Malek, Ehsan
    Haque, Sulsal
    Sendilnathan, Arun
    Huth, Bradley Joseph
    Morris, John Charles
    Karim, Nagla Abdel
    Latif, Tahir
    Redmond, Kevin P.
    Barrett, William
    Videtic, Gregory M. M.
    Sadraei, Nooshin Hashemi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] SPIROMETRY IN PATIENTS WITH STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC)
    Mendis, R.
    McDonald, C. F.
    John, T.
    O'Donoghue, F. J.
    White, S. C.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S75 - S75
  • [46] Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC)
    Gijtenbeek, Rolof G. P.
    Helfrich, Gea
    Venmans, Ben J. W.
    Ten Brinke, Anneke
    De Jong, Kim
    Van Geffen, Wouter H.
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [47] Did dose escalated radiotherapy in stage III non-small cell lung cancer improve overall survival?
    Wang, Wei-Wei
    Wang, Shao-Jia
    Zhou, Zhi-Rui
    JOURNAL OF THORACIC DISEASE, 2016, 8 (11) : 3338 - 3342
  • [48] Polymorphisms in ERCC2 and overall survival (OS) in early stage non-small cell lung cancer (NSCLC).
    Suk, R
    Park, S
    Liu, G
    Cogan-Drew, T
    Zhou, W
    Su, L
    Lynch, T
    Wain, J
    Christiani, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 842S - 842S
  • [49] SURVIVAL OF PATIENTS WITH BRAIN METASTASES AND NON-SMALL CELL LUNG CANCER (NSCLC)
    Randhawa, J. K.
    Patel, S. P.
    Stokes, T. C.
    THORAX, 2009, 64 : A148 - A148
  • [50] Predictors of Subsequent Lines of Therapy (LOTs) in Non-Small Cell Lung Cancer (NSCLC)
    Nadler, Eric
    Penrod, John R.
    Espirito, Janet L.
    Wilson, Thomas
    Patt, Debra A.
    Korytowsky, Beata
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S655 - S655
12345